Loading
Pediatric Health and Respiratory Diseases / Streptococcal Infections and Treatments · Journal article
Профилактическая Медицина И Здоровье · August 3, 2026
Encouraging direction, but not yet definitive.
This is a single-centre, two-arm RCT of Biodonatum, a postbiotic preparation, added to standard antibiotic therapy in 90 children aged 3–14 years with community-acquired pneumonia and reduced antibiotic susceptibility. The source describes the study protocol and population but does not report clinical outcomes, effect sizes, or statistical significance.
Prospective, randomized, controlled clinical trial. Children aged 3 to 14 years with confirmed community-acquired pneumonia and documented reduced sensitivity to antibiotics, enrolled at the Department of Pediatric Infectious Diseases of Tashkent State Medical University.. Intervention: Standard antibiotic therapy supplemented with Biodonatum (a postbiotic preparation). Compared with: Standard antibiotic therapy alone. n = 90. Tashkent State Medical University, Uzbekistan.
90 children aged 3 to 14 years with confirmed community-acquired pneumonia and documented reduced sensitivity to antibiotics were enrolled Intervention group (n = 45) received standard antibiotic therapy supplemented with Biodonatum; control group (n = 45) received standard antibiotic therapy alone Clinical, laboratory, and microbiological parameters were assessed at baseline and on days 7 and 14 of treatment
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This trial addresses an important gap in treatment for antibiotic-resistant pediatric pneumonia, but clinicians cannot yet assess efficacy or safety because outcomes are not reported in the source text. Completion and publication of results is needed before clinical recommendations can be made.
A single-centre RCT of modest size testing an adjunctive postbiotic in antibiotic-resistant pediatric pneumonia, with clinical endpoints measured over 14 days, but without reported effect sizes, p-values, or outcomes.
As stated by the source record.
Quoted from the source exactly as published.
This trial addresses an important gap in treatment for antibiotic-resistant pediatric pneumonia, but clinicians cannot yet assess efficacy or safety because outcomes are not reported in the source text. Completion and publication of results is needed before clinical recommendations can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Community-acquired pneumonia remains one of the leading causes of morbidity and mortality among children worldwide, while antimicrobial resistance poses an increasing threat to successful clinical treatment. The emergence and rapid spread of antibiotic-resistant bacterial strains have significantly reduced the therapeutic options available to physicians treating pediatric pneumonia, necessitating the exploration of adjunctive treatment strategies capable of improving clinical recovery and restoring microbial balance. This study was conducted to evaluate the clinical efficacy, safety profile, and microbiome-modulating effects of the postbiotic preparation Biodonatum when used as an adjunct to standard antibiotic therapy in children diagnosed with community-acquired pneumonia and exhibiting reduced susceptibility to first-line antibiotics. A prospective, randomized, controlled clinical trial was conducted at the Department of Pediatric Infectious Diseases of the Tashkent State Medical University. The study enrolled 90 children aged 3 to 14 years with confirmed community-acquired pneumonia and documented reduced sensitivity to antibiotics. Participants were randomly assigned to two equal groups: the intervention group (n = 45) received standard antibiotic therapy supplemented with Biodonatum, while the control group (n = 45) received standard antibiotic therapy alone. Clinical, laboratory, and microbiological parameters were assessed at baseline and on days 7 and 14 of treatment.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.